Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know

Shares of Capricor Therapeutics (CAPR) have gained 11.9% over the past four weeks to close the last trading session at $6.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$21 indicates a potential upside of 218.2%.The average comprises four short-term price targets ranging from a low of $8 to a high of$40, with a standard deviation of $14.38. While the lowest estimate indica ...